Fixed character in ORU files (#903)

examples/MN/004_MN_ORU_R01_NBS_0_initial_message.hl7

@@ -5,7 +5,7 @@ ORC|RE|423787478^EPIC^1.2.840.114350.1.13.145.2.7.2.695071^ISO|20231561137^MN Pu
 OBR|1|423787478^EPIC^1.2.840.114350.1.13.145.2.7.2.695071^ISO|20231561137^MN Public Health Lab^2.16.840.1.114222.4.1.10080^ISO|57128-1^Newborn Screening Report summary panel^LN|||20230603045000||||O|||||1174911127^SMITH^SAMANTHA^^^^^^NPI^L^^^NPI||||||20230606191613|||F||||423787478&EPIC&1.2.840.114350.1.13.145.2.7.2.695071&ISO^20231561137&MN Public Health Lab&2.16.840.1.114222.4.1.10080&ISO|||||||||||||||||||||54089-8^Newborn screening panel American Health Information Community (AHIC)^LN|
 OBX|1|CWE|57718-9^Sample quality of Dried blood spot^LN|^1^1|LA12432-3^Acceptable^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||RSLT|UNSP|
 OBX|2|CWE|57130-7^Newborn screening report - overall interpretation^LN|^2^1|LA12428-1^All screening is in range for the conditions tested^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||RSLT|UNSP|
-OBX|3|FT|69969-4^Newborn screening report overall laboratory comment^LN|^3^1|Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\.br\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\.br\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\.br\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\.br\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\.br\ ||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||RSLT|UNSP|
+OBX|3|FT|69969-4^Newborn screening report overall laboratory comment^LN|^3^1|Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\.br\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\.br\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\.br\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\.br\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\.br\ ||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||RSLT|UNSP|
 OBX|4|FT|69969-4^Newborn screening report overall laboratory comment^LN|^3^2|There is decreased sensitivity in screening for CMV in dried blood spots, so not all infants with congenital CMV will be identified. Of those who are identified by newborn screening, up to 80% will be unaffected.||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||RSLT|UNSP|
 OBX|5|CWE|57719-7^Conditions tested for in this newborn screening study [Identifier] in DBS^LN|^4^1|LA12538-7^CH^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||SCI|UNSP|
 OBX|6|CWE|57719-7^Conditions tested for in this newborn screening study [Identifier] in DBS^LN|^4^2|LA22202-8^CF^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory^^^^^|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie^^^^^^||||SCI|UNSP|

examples/MN/004_MN_ORU_R01_NBS_1_hl7_translation.fhir

@@ -1291,7 +1291,7 @@
             "reference": "PractitionerRole/1708034743623273379.43c91689-43fc-4826-9f1e-c6200571b620"
           }
         ],
-        "valueString": "Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\\.br\\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\\.br\\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\\.br\\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\\.br\\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\\.br\\ "
+        "valueString": "Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\\.br\\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\\.br\\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\\.br\\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\\.br\\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\\.br\\ "
       }
     },
     {

examples/MN/004_MN_ORU_R01_NBS_2_fhir_transformation.fhir

@@ -1296,7 +1296,7 @@
             "reference": "PractitionerRole/1708034743623273379.43c91689-43fc-4826-9f1e-c6200571b620"
           }
         ],
-        "valueString": "Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\\.br\\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\\.br\\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\\.br\\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\\.br\\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\\.br\\ "
+        "valueString": "Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\\.br\\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\\.br\\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\\.br\\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\\.br\\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\\.br\\ "
       }
     },
     {

examples/MN/004_MN_ORU_R01_NBS_3_hl7_translation_final.hl7

@@ -5,7 +5,7 @@ ORC|RE|423787478^EPIC^1.2.840.114350.1.13.145.2.7.2.695071^ISO|20231561137^MN Pu
 OBR|1|423787478^EPIC^1.2.840.114350.1.13.145.2.7.2.695071^ISO|20231561137^MN Public Health Lab^2.16.840.1.114222.4.1.10080^ISO|57128-1^Newborn Screening Report summary panel^LN|||20230603045000||||O|||||1174911127^SMITH^SAMANTHA^^^^^^NPI^L^^^NPI||||||20230606191613|||F||||423787478&EPIC&1.2.840.114350.1.13.145.2.7.2.695071&ISO^20231561137&MN Public Health Lab&2.16.840.1.114222.4.1.10080&ISO|||||||||||||||||||||54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
 OBX|1|CWE|57718-9^Sample quality of Dried blood spot^LN||LA12432-3^Acceptable^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP
 OBX|2|CWE|57130-7^Newborn screening report - overall interpretation^LN||LA12428-1^All screening is in range for the conditions tested^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP
-OBX|3|FT|69969-4^Newborn screening report overall laboratory comment^LN||Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here:�https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\.br\The�purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\.br\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\.br\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\.br\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\.br\ ||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP
+OBX|3|FT|69969-4^Newborn screening report overall laboratory comment^LN||Resources: An MDH genetic counselor is available for consultation regarding screening results at 651-201-3548. Disorder fact sheets and specialist contact list can be found here: https://www.health.state.mn.us/people/newbornscreening/materials/factsheets/bloodspotdisorders.html\.br\The purpose of newborn screening is to identify at risk infants in need of diagnostic testing. As with any screening test, false positive or false negative results are possible. Newborn screening is insufficient information on which to base, or rule out, diagnosis or treatment. CF variant analysis is completed using the Luminex xTAG Cystic Fibrosis (CFTR) 39 Kit.\.br\*This real-time PCR assay was developed and its performance characteristics were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration: 21 CFR 809.30(e).\.br\**The performance characteristics of these tests were determined by the MDH Public Health Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration.\.br\***Testing is performed by Mayo Clinic Laboratories-Rochester Main Campus; 200 First Street SW, Rochester, MN 55905\.br\ ||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP
 OBX|4|FT|69969-4^Newborn screening report overall laboratory comment^LN||There is decreased sensitivity in screening for CMV in dried blood spots, so not all infants with congenital CMV will be identified. Of those who are identified by newborn screening, up to 80% will be unaffected.||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP
 OBX|5|CWE|57719-7^Conditions tested for in this newborn screening study [Identifier] in DBS^LN||LA12538-7^CH^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP
 OBX|6|CWE|57719-7^Conditions tested for in this newborn screening study [Identifier] in DBS^LN||LA22202-8^CF^LN||||||F|||20230603045000|||||20230606191613||||MDH Newborn Screening Laboratory|601 Robert St N^^St. Paul^MN^55155|^Miller^Marie|||||UNSP